In contrast, insulin-treated patients had a higher prevalence of NAFLD (39.4% vs. 25%, p < 0.001), in agreement with previous evidence suggesting exogenous insulin leads to hepatic fat accumulation due to its anabolic effect on lipid metabolism [20]. This evidence concerns the gene INS and metabolic dysfunction-associated steatotic liver disease.